On June 18, Qingsong Health (02661.HK) rose 10.21% in regular trading, reaching HKD 14.56 per share, with turnover of HKD 115 million — significantly above recent daily averages.

The rebound comes amid a cluster of positive developments. The company recently unveiled its Evidence Mirror AI glasses system at CES Asia, the worlds first evidence-based medical AI eyewear designed for real clinical workflows including consultations, ward rounds, and remote collaboration. Simultaneously, operational data disclosed on June 16 showed user growth exceeding 40% in the first five months of the year, with AI Token consumption surging 5x year-over-year, signaling accelerating adoption of its medical AI capabilities.

Additionally, the company signed a strategic cooperation memorandum with Singapore-listed Basel Medical Group to deploy its AIcare technology stack in Southeast Asia, marking a substantive step in its internationalization strategy. Multiple market commentaries have characterized the product launches and usage metrics as potential catalysts for valuation reassessment, noting the stock had declined over 85% from its March all-time high amid lock-up expiry concerns and thin liquidity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)